Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development (Q38088759)

28 August 2017

title

Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development (English)

1 reference

28 August 2017

0 references

Hala Gali-Muhtasib

0 references

Nadine Darwiche

series ordinal

object named as

Nadine Darwiche

1 reference

28 August 2017

Sara El-Banna

1 reference

28 August 2017

Hala Gali-Muhtasib

series ordinal

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

361-379

1 reference

Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Natural products as sources of new drugs over the period 1981-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Plants as a source of anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Modulating cell cycle: current applications and prospects for future drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Camptothecin and taxol: historic achievements in natural products research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Novel aspects of natural and modified vinca alkaloids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Activity of vinorelbine in gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Mechanism of action of antitumor drugs that interact with microtubules and tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Resistance to apoptosis of HCW-2 cells can be overcome by curcumin- or vincristine-induced mitotic catastrophe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Vinflunine: a novel antitubulin agent in solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Current challenges in Wilms' tumor management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Emerging drugs for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Structure-activity relationships of VP-16 analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Etoposide, topoisomerase II and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Taxol induces caspase-10-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Alterations in protein expression in HL-60 cells during etoposide-induced apoptosis modulated by the caspase inhibitor ZVAD.fmk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Docetaxel: a review of its use in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Chromosomal instability, colorectal cancer and taxane resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Cellular FLICE-like inhibitory protein (c-FLIP): a novel target for Taxol-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Induction of caspase-3-dependent apoptosis in human leukemia HL-60 cells by paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

21 January 2018

The taxanes: an update

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Necessity of interleukin-1beta converting enzyme cascade in taxotere-initiated death signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Cyclin A-associated kinase activity is needed for paclitaxel sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Review camptothecin: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Topoisomerase I inhibitors: camptothecins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

S-phase modulation by irinotecan: pilot studies in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Nuclear caspase-3 and caspase-7 activation, and poly(ADP-ribose) polymerase cleavage are early events in camptothecin-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Irinotecan in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Homoharringtonine: a new treatment option for myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Inhibition of Translation in Eukaryotic Systems by Harringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Cytotoxicity and cell cycle specificity of homoharringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Multimodal action of antitumor agents on DNA: the ellipticine series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Rescue of mutant p53 transcription function by ellipticine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Inhibition of p53 Protein Phosphorylation by 9‐Hydroxyellipticine: A Possible Anticancer Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Flavopiridol, an inhibitor of transcription: implications, problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Mechanisms of action of flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

From chemoprevention to chemotherapy: common targets and common goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Medicinal chemistry of combretastatin A4: present and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Combretastatin A4 phosphate: background and current clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Combretastatin A4 phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Endothelial cell proliferation as a novel approach to targeting tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Roscovitine targets, protein kinases and pyridoxal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Replication-dependent DNA damage response triggered by roscovitine induces an uncoupling of DNA replication proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Cyclotherapy: protection of normal cells and unshielding of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Functional genomics to new drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Drug discovery from medicinal plants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Trends in development and approval times for new therapeutics in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Key factors in the rising cost of new drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

The evolving role of natural products in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Lessons from natural molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.3.361

Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1124/MOL.105.016154

Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.1139/V87-399

Identifiers

DOI

10.1517/17460441.2.3.361

1 reference

release_jx4hsyfvcjht7palwcq6eutwwa

28 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jx4hsyfvcjht7palwcq6eutwwa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference